Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
We've made it easier for you to connect! Fill out your NEW profile.

AIs vs. Tamoxifen for Pre-Menopausal Women W/ Early-Stage, HR+

Study Compares Aromatase Inhibitors vs. Tamoxifen for Pre-Menopausal Women With Early-Stage, Hormone Receptor-Positive Breast Cancer
December 15, 2021

Pre-menopausal women diagnosed with early-stage, hormone receptor-positive breast cancer who took an aromatase inhibitor along with ovarian suppression after surgery had a 3.2% lower risk of recurrence than women who took tamoxifen after surgery. Still, there was no difference in overall survival. Read more...